Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT00430014Phase 1Terminated

Study of Atiprimod Treatment for Patients With Advanced Cancer

Role: collaborator

NCT00663429Phase 2Completed

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

Role: lead

NCT00430443Phase 1Terminated

Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

Role: lead

NCT00086216Phase 1Completed

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

Role: lead

NCT00388063Phase 2Completed

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Role: lead

NCT00271063Phase 1Unknown

Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia

Role: lead

NCT00214838Phase 1Unknown

An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Advanced Cancer

Role: lead

All 7 trials loaded